Longeveron Inc. (NASDAQ: LGVN) announced a $30 million private placement, with an initial $15 million tranche expected to close on March 11 2026. The deal is led by Coastlands Capital and includes participation from Janus Henderson Investors, Logos Capital and Kalehua Capital.
The placement is structured as common shares and convertible preferred stock priced at 52 cents per share under Nasdaq’s at‑the‑market rules. Investors will receive 50 % of any proceeds from a future sale of a Rare Pediatric Disease Priority Review Voucher (PRV) if the FDA grants one for Longeveron's hypoplastic left heart syndrome (HLHS) program.
The financing extends Longeveron’s cash runway into the fourth quarter of 2026, beyond the anticipated readout of the pivotal Phase 2b ELPIS II trial. The company’s accumulated deficit of $126.90 million and a recent 12‑month cash burn of roughly $17 million underscore the liquidity pressure that the new capital is designed to relieve.
Longeveron’s HLHS program, the focus of the ELPIS II trial, has received FDA orphan drug, fast‑track and rare pediatric disease designations. The PRV program, reauthorized through September 2029, offers a potential upside that is reflected in the investor incentive structure. The company also maintains research programs in Alzheimer’s disease and pediatric dilated cardiomyopathy, but the HLHS pipeline remains the primary driver of the current financing.
Investors reacted strongly to the announcement, citing the lifeline the placement provides to a micro‑cap biotech with no revenue and significant R&D costs. The deal’s milestone‑linked structure and potential PRV upside were highlighted as key factors that bolstered confidence in Longeveron's ability to advance its HLHS program and pursue partnership negotiations.
The private placement is not a transformative acquisition but is a material event that strengthens Longeveron’s financial position and supports continued progress toward regulatory milestones, manufacturing scale‑up and potential commercialization of its pipeline assets.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.